Anticancer Section / Original Paper

Li X.a,b· Chen X.a,b· Fu C.a,b· Xie M.a,b· Ouyang S.a,b

Author affiliations

aDepartment of Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, China
bDepartment of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: August 17, 2022
Accepted: December 27, 2022
Published online: January 19, 2023

Number of Print Pages: 12
Number of Figures: 5
Number of Tables: 1

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Abstract

Background: Oxaliplatin-based chemotherapy resistance is a major cause of recurrence in patients with colorectal cancer (CRC). Increasing evidence indicates that lncRNA BCAR4 is involved in the occurrence and development of various cancers. However, the effect of BCAR4 on CRC chemotherapy resistance remains unclear. Methods: Real-time quantitative PCR and Western blotting were used to detect the expression levels of gene and protein, respectively. The role of BCAR4 in drug resistance was evaluated by cell viability and apoptosis experiments. Luciferase reporter assay and Western blot analysis confirmed the relationship between BCAR4, miR-483-3p, and RAB5C. Results: Luciferase reporter assay and Western blotting analysis confirmed the relationship among BCAR4, miR-483-3p, and RAB5C. The results showed that the expression levels of BCAR4 and RAB5C were increased in CRC tumor tissue. The expression levels of BCAR4 were increased in patients with chemotherapy resistance. Functional analysis showed that knockdown of BCAR4 reduced the expression levels of proteins related to stemness, decreased the activity of cells, and promoted apoptosis of CRC cells, while overexpression of RAB5C reversed these effects. Moreover, the results showed that BCAR4 promoted oxaliplatin resistance by inhibiting cell apoptosis. Mechanistically, BCAR4 sponged miR-483-3p and promoted the expression of RAB5C. Knockdown of BCAR4 reduced tumor size and enhanced cell sensitivity to oxaliplatin in vivo. Conclusion: The results suggested that BCAR4/miR-483-3p/RAB5C axis has the potential to be explored as a novel therapeutic target for CRC treatment.

© 2023 S. Karger AG, Basel

References Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol. 2003;16(4):376–88. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9. Meijer D, van Agthoven T, Bosma PT, Nooter K, Dorssers LCJ. Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res. 2006;4(6):379–86. Wang X, Jiang G, Ren W, Wang B, Yang C, Li M. LncRNA NEAT1 regulates 5-fu sensitivity, apoptosis and invasion in colorectal cancer through the MiR-150-5p/CPSF4 Axis. Onco Targets Ther. 2020;13:6373–83. Wang B, Xu W, Cai Y, Liu K, Wu J, Guo C, et al. The functional role of oncogenic LncRNA BCAR4 for cancer outcome. Curr Pharm Des. 2021;27(39):4107–13. Zhang Y, Zhou H. LncRNA BCAR4 promotes liver cancer progression by upregulating ANAPC11 expression through sponging miR1261. Int J Mol Med. 2020;46(1):159–66. Gan FJ, Li Y, Xu MX, Zhou T, Wu S, Hu K, et al. LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Cancer Biomark. 2021;32(3):339–51. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–52. Zhang F, Li K, Yao X, Wang H, Li W, Wu J, et al. A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer. EBioMedicine. 2019;44:311–21. Wang WW, Zhao ZH, Wang L, Li P, Chen KS, Zhang JY, et al. MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway. EBioMedicine. 2019;46:66–78. Liu S, Cheng K, Zhang H, Kong R, Wang S, Mao C, et al. Methylation status of the nanog promoter determines the switch between cancer cells and cancer stem cells. Adv Sci. 2020;7(5):1903035. Meier C, Hardtstock P, Joost S, Alla V, Putzer BM. p73 and IGF1R regulate emergence of aggressive cancer stem-like features via miR-885-5p control. Cancer Res. 2016;76(2):197–205. Reddy KB. MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015;15:38. Huang WK, Shi H, Akcakaya P, Zeljic K, Gangaev A, Caramuta S, et al. Imatinib regulates miR-483-3p and mitochondrial respiratory complexes in gastrointestinal stromal tumors. Int J Mol Sci. 2021;22(19):10600. Zhang L, Ruan Y, Qin Z, Gao X, Xu K, Shi X, et al. miR-483-3p, mediated by KLF9, functions as tumor suppressor in testicular seminoma via targeting MMP9. Front Oncol. 2020;10:596574. Woodman PG. Biogenesis of the sorting endosome: the role of Rab5. Traffic. 2000;1(9):695–701. Chen PI, Kong C, Su X, Stahl PD. Rab5 isoforms differentially regulate the trafficking and degradation of epidermal growth factor receptors. J Biol Chem. 2009;284(44):30328–38. Wainszelbaum MJ, Proctor BM, Pontow SE, Stahl PD, Barbieri MA. IL4/PGE2 induction of an enlarged early endosomal compartment in mouse macrophages is Rab5-dependent. Exp Cell Res. 2006;312(12):2238–51. Baptistella AR, Landemberger MC, Dias MVS, Giudice FS, Rodrigues BR, da Silva PPCE, et al. Rab5C enhances resistance to ionizing radiation in rectal cancer. J Mol Med. 2019;97(6):855–69. Liu T, Zhang X, Du L, Wang Y, Liu X, Tian H, et al. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer. Mol Cancer. 2019;18(1):43. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, et al. Exosome-Transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29(5):653–68. Wang S, Wang L, Hu H, Dong P. MiR-224 ameliorates inflammation and symptoms in mouse model of allergic rhinitis by targeting CDK9. Allergol Immunopathol. 2021;49(6):80–8. Liang Z, Zhang X, Liu Y, Wu Q, You C. SEMA3A protects against hyperoxia-induced lung injury in a bronchopulmonary dysplasia model of newborn rat by inhibiting ERK pathway. Allergol Immunopathol. 2021;49(6):8–15. Qian XL, Zhou F, Xu S, Jiang J, Chen ZP, Wang SK, et al. MiR-454-3p promotes oxaliplatin resistance by targeting PTEN in colorectal cancer. Front Oncol. 2021;11:638537. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8(5):486–98. Zhang Y, Xu W, Guo H, Zhang Y, He Y, Lee SH, et al. NOTCH1 signaling regulates self-renewal and platinum chemoresistance of cancer stem-like cells in human non-small cell lung cancer. Cancer Res. 2017;77(11):3082–91. Pointer KB, Clark PA, Eliceiri KW, Salamat MS, Robertson GA, Kuo JS. Administration of non-torsadogenic human ether-a-go-go-related gene inhibitors is associated with better survival for high hERG-expressing glioblastoma patients. Clin Cancer Res. 2017;23(1):73–80. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, editor. Guide for the Care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press (US); 2011. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Diz PG, Rey JM, Garcia-Garcia A. Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases. Cancer Lett. 2010;295(2):135–43. Marie JP. P-glycoprotein in adult hematologic malignancies. Hematol Oncol Clin North Am. 1995;9(2):239–50. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst. 1991;83(2):111–6. Hsu HH, Chen MC, Baskaran R, Lin YM, Day CH, Lin YJ, et al. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol. 2018;233(7):5458–67. Mou Y, He N, Su M, Zhong Z, Ma J, Liu J, et al. MiR-1254 and MEGF6 regulates oxaliplatin resistance in human colorectal cancer cells. Am J Transl Res. 2021;13(1):183–96. Bae K, Kim JH, Jung H, Kong SY, Kim YH, Kim S, et al. A fusion of CD63-BCAR4 identified in lung adenocarcinoma promotes tumorigenicity and metastasis. Br J Cancer. 2021;124(1):290–8. 33204025 Zhang R, Wang J, Jia E, Zhang J, Liu N, Chi C. lncRNA BCAR4 sponges miR-370-3p to promote bladder cancer progression via Wnt signaling. Int J Mol Med. 2020;45(2):578–88. Cai Z, Wu Y, Ju G, Wang G, Liu B. Role of BCAR4 in prostate cancer cell autophagy. Transl Androl Urol. 2021;10(11):4253–61. Wang L, Chunyan Q, Zhou Y, He Q, Ma Y, Ga Y, et al. BCAR4 increase cisplatin resistance and predicted poor survival in gastric cancer patients. Eur Rev Med Pharmacol Sci. 2021;25(7):2822. Roskoski R, Jr. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacol Res. 2019;142:151–68. Wang H. MicroRNAs and apoptosis in colorectal cancer. Int J Mol Sci. 2020;21(15):5353. Sciarrillo R, Wojtuszkiewicz A, Assaraf YG, Jansen G, Kaspers GJL, Giovannetti E, et al. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resist Updat. 2020;53:100728. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–27. Wong CC, Xu J, Bian X, Wu JL, Kang W, Qian Y, et al. In colorectal cancer cells with mutant KRAS, slc25a22-mediated glutaminolysis reduces DNA demethylation to increase WNT signaling, stemness, and drug resistance. Gastroenterology. 2020;159(6):2163–80.e6. In Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun (Lond). 2021;41(3):199–217. Panigoro SS, Kurnia D, Kurnia A, Haryono SJ, Albar ZA. ALDH1 cancer stem cell marker as a prognostic factor in triple-negative breast cancer. Int J Surg Oncol. 2020;2020:7863243. 32695508 Liesche F, Griessmair M, Barz M, Gempt J, Schlegel J. ALDH1 - a new immunohistochemical diagnostic marker for Schwann cell-derived tumors. Clin Neuropathol. 2019;38(4):168–73. Barbera S, Nardi F, Elia I, Realini G, Lugano R, Santucci A, et al. The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration. Cell Commun Signal. 2019;17(1):55. Li YM, Xu C, Sun B, Zhong FJ, Cao M, Yang LY. Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF-beta signaling by recruiting Rab5c. Cancer Cell Int. 2022;22(1):162. Yang Y, Yujiao W, Fang W, Linhui Y, Ziqi G, Zhichen W, et al. The roles of miRNA, lncRNA and circRNA in the development of osteoporosis. Biol Res. 2020;53(1):40. Xu J, Wu KJ, Jia QJ, Ding XF. Roles of miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ Sci B. 2020;21(9):673–89. Wu K, Wang J, He J, Chen Q, Yang L. miR-483-3p promotes proliferation and migration of neuroblastoma cells by targeting PUMA. Int J Clin Exp Pathol. 2018;11(2):490–501. Article / Publication Details

First-Page Preview

Received: August 17, 2022
Accepted: December 27, 2022
Published online: January 19, 2023

Number of Print Pages: 12
Number of Figures: 5
Number of Tables: 1

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.